The Report
Verified funding, headquarters, and leadership news from the world's most innovative businesses
323 reports and counting
Breye Therapeutics Raises €67.5M Series A for Oral Retinal Disease Drugs
Breye Therapeutics raised an over-subscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into a Phase 2 trial.
Slingshot Biosciences Appoints Dr. Nimisha Srivastava CEO
Slingshot Biosciences promoted Chief Operating Officer Dr. Nimisha Srivastava to CEO to lead commercial growth and product development.
Claris Bio Relocates Corporate Headquarters to South San Francisco
Claris Bio will relocate its corporate headquarters from Jersey City to South San Francisco in October 2026 as it advances CSB-001.
Basecamp Research Raises $140M Series C for AI-Designed Medicines
Basecamp Research raised a $140 million Series C led by S32 to train new EDEN models and advance AI-designed therapeutics toward clinical development.
Cloverleaf Bio Raises $33M Seed Round for RNA Cancer Therapeutics
Cloverleaf Bio closed an oversubscribed $33 million seed round to advance engineered tRNA therapeutics for liver and colorectal cancers.
Teletrac Navman Appoints Ricardo Buranello Chief Executive Officer
Teletrac Navman named Chief Financial and Operating Officer Ricardo Buranello its next CEO, effective October 1, 2026, succeeding Alain Samaha.
NovaGo Therapeutics Raises $30M Series B for Spinal Cord Injury Study
NovaGo Therapeutics raised a $30 million Series B led by Neurimmune and Pureos Bioventures to advance a proof-of-concept study in acute spinal cord injury.
Choice Hotels Appoints Dominic Dragisich President and Chief Executive Officer
Choice Hotels’ Board appointed Interim CEO Dominic Dragisich as President and Chief Executive Officer and a director, with a focus on disciplined execution and growth.
AusperBio Raises $120M Series C for Hepatitis B Oligonucleotide Therapies
AusperBio closed a $120 million Series C led by a strategic investor, with new investor RA Capital participating, to advance its hepatitis B candidate AHB-137.
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.